Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Krystal Biotech, Inc.KRYS · Entity 3500 | Director · President, R&D · 10% owner | September 04, 2026 | September 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Krystal Biotech, Inc.
Report date September 04, 2026 · Filed September 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,302,145 |
Ending reported balance
After 2026-09-04 transaction · row 13
13 source rows · reconciled sequenceRow 1 · 2026-09-04 · Sale · Disposed 520 · Balance 1,326,625 F1: The Reporting Person may be deemed to beneficially own shares of the Issuer's common stock directly owned by the Reporting Person's spouse, Krish S. Krishnan. Such shares and transactions by the Reporting Person's spouse are not included in this Form 4, as they are being reported separately on a Form 4 filed by her spouse. The Reporting Person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein. F2: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025. The Rule 10b5-1 trading plan has reached the maximum number of shares to be sold under such plan and has terminated. F3: The transaction was executed in multiple trades ranging from $353.98 to $354.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 2 · 2026-09-04 · Sale · Disposed 2,006 · Balance 1,324,619 F4: The transaction was executed in multiple trades ranging from $354.98 to $355.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 3 · 2026-09-04 · Sale · Disposed 3,267 · Balance 1,321,352 F5: The transaction was executed in multiple trades ranging from $355.98 to $356.96. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 4 · 2026-09-04 · Sale · Disposed 3,962 · Balance 1,317,390 F6: The transaction was executed in multiple trades ranging from $356.99 to $357.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 5 · 2026-09-04 · Sale · Disposed 3,180 · Balance 1,314,210 F7: The transaction was executed in multiple trades ranging from $357.99 to $358.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 6 · 2026-09-04 · Sale · Disposed 3,392 · Balance 1,310,818 F8: The transaction was executed in multiple trades ranging from $358.99 to $359.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 7 · 2026-09-04 · Sale · Disposed 2,320 · Balance 1,308,498 F9: The transaction was executed in multiple trades ranging from $360.01 to $361.005. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 8 · 2026-09-04 · Sale · Disposed 1,242 · Balance 1,307,256 F10: The transaction was executed in multiple trades ranging from $361.02 to $362.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 9 · 2026-09-04 · Sale · Disposed 1,992 · Balance 1,305,264 F11: The transaction was executed in multiple trades ranging from $362.02 to $363.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 10 · 2026-09-04 · Sale · Disposed 565 · Balance 1,304,699 F12: The transaction was executed in multiple trades ranging from $363.05 to $364.01. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 11 · 2026-09-04 · Sale · Disposed 1,329 · Balance 1,303,370 F13: The transaction was executed in multiple trades ranging from $364.07 to $365.05. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 12 · 2026-09-04 · Sale · Disposed 826 · Balance 1,302,544 F14: The transaction was executed in multiple trades ranging from $365.07 to $366.03. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 13 · 2026-09-04 · Sale · Disposed 399 · Balance 1,302,145 F15: The transaction was executed in multiple trades ranging from $366.39 to $366.91. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| Common StockSEC Table I · non-derivative | IndirectBy Krishnan Spousal Trust | 90,000 |
Reported balance
Holding disclosure · report date 2026-09-04 · row 14
Holding and transaction disclosures are not merged.
1 source rowRow 14 · Balance 90,000 F16: Held by the Krishnan Spousal Trust, an irrevocable trust established by Mr. Krishnan for the benefit of Mrs. Krishnan who serves as a co-trustee and shares voting and investment power with a 3rd party co-trustee. |
| Common StockSEC Table I · non-derivative | IndirectBy Suma Mani Krishnan Trust | 51,010 |
Reported balance
Holding disclosure · report date 2026-09-04 · row 15
Holding and transaction disclosures are not merged.
1 source rowRow 15 · Balance 51,010 F17: Held by the Suma Mani Krishnan Trust dated July 7, 2026. The Reporting Person is the grantor and trustee of the trust, has the power to revoke the trust, and has voting and investment power with respect to the shares held by the trust. |
| Common StockSEC Table I · non-derivative | IndirectBy Krishnan Family Trust | 50,000 |
Reported balance
Holding disclosure · report date 2026-09-04 · row 16
Holding and transaction disclosures are not merged.
1 source rowRow 16 · Balance 50,000 F18: Held by the Krishnan Family Trust. The Reporting Person and her spouse are each joint beneficial owners of the trust with joint voting and investment control. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person may be deemed to beneficially own shares of the Issuer's common stock directly owned by the Reporting Person's spouse, Krish S. Krishnan. Such shares and transactions by the Reporting Person's spouse are not included in this Form 4, as they are being reported separately on a Form 4 filed by her spouse. The Reporting Person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein.
F2: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025. The Rule 10b5-1 trading plan has reached the maximum number of shares to be sold under such plan and has terminated.
F3: The transaction was executed in multiple trades ranging from $353.98 to $354.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F4: The transaction was executed in multiple trades ranging from $354.98 to $355.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F5: The transaction was executed in multiple trades ranging from $355.98 to $356.96. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F6: The transaction was executed in multiple trades ranging from $356.99 to $357.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F7: The transaction was executed in multiple trades ranging from $357.99 to $358.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F8: The transaction was executed in multiple trades ranging from $358.99 to $359.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F9: The transaction was executed in multiple trades ranging from $360.01 to $361.005. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F10: The transaction was executed in multiple trades ranging from $361.02 to $362.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F11: The transaction was executed in multiple trades ranging from $362.02 to $363.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F12: The transaction was executed in multiple trades ranging from $363.05 to $364.01. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F13: The transaction was executed in multiple trades ranging from $364.07 to $365.05. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F14: The transaction was executed in multiple trades ranging from $365.07 to $366.03. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F15: The transaction was executed in multiple trades ranging from $366.39 to $366.91. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F16: Held by the Krishnan Spousal Trust, an irrevocable trust established by Mr. Krishnan for the benefit of Mrs. Krishnan who serves as a co-trustee and shares voting and investment power with a 3rd party co-trustee.
F17: Held by the Suma Mani Krishnan Trust dated July 7, 2026. The Reporting Person is the grantor and trustee of the trust, has the power to revoke the trust, and has voting and investment power with respect to the shares held by the trust.
F18: Held by the Krishnan Family Trust. The Reporting Person and her spouse are each joint beneficial owners of the trust with joint voting and investment control.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2024 Filed Jun 12, 2024 00:33 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 4,975 | $175.33 | $872,273.22 |
DisclosureSEC source: 0001298711-24-000011 · wk-form4_1718152417.xml · nonDerivative · entry 5 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,539,978 F1 · kind: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on September 11, 2023, and contemplated quarterly sales of 25,000 shares with a limit price of $100.00 per share. The Rule 10b5-1 trading plan has reached the maximum number of shares to be sold under such plan and has terminated. F6 · price: The transaction was executed in multiple trades ranging from $174.85 to $175.83. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| June 11, 2024 Filed Jun 12, 2024 00:33 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 1,724 | $174.50 | $300,831.45 |
DisclosureSEC source: 0001298711-24-000011 · wk-form4_1718152417.xml · nonDerivative · entry 4 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,544,953 F1 · kind: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on September 11, 2023, and contemplated quarterly sales of 25,000 shares with a limit price of $100.00 per share. The Rule 10b5-1 trading plan has reached the maximum number of shares to be sold under such plan and has terminated. F5 · price: The transaction was executed in multiple trades ranging from $173.85 to $174.83. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| June 11, 2024 Filed Jun 12, 2024 00:33 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 1,206 | $173.41 | $209,137.28 |
DisclosureSEC source: 0001298711-24-000011 · wk-form4_1718152417.xml · nonDerivative · entry 3 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,546,677 F1 · kind: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on September 11, 2023, and contemplated quarterly sales of 25,000 shares with a limit price of $100.00 per share. The Rule 10b5-1 trading plan has reached the maximum number of shares to be sold under such plan and has terminated. F4 · price: The transaction was executed in multiple trades ranging from $172.85 to $173.80. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| June 11, 2024 Filed Jun 12, 2024 00:33 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 2,099 | $172.24 | $361,528.61 |
DisclosureSEC source: 0001298711-24-000011 · wk-form4_1718152417.xml · nonDerivative · entry 2 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,547,883 F1 · kind: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on September 11, 2023, and contemplated quarterly sales of 25,000 shares with a limit price of $100.00 per share. The Rule 10b5-1 trading plan has reached the maximum number of shares to be sold under such plan and has terminated. F3 · price: The transaction was executed in multiple trades ranging from $171.84 to $172.81. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| June 11, 2024 Filed Jun 12, 2024 00:33 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 900 | $171.40 | $154,256.58 |
DisclosureSEC source: 0001298711-24-000011 · wk-form4_1718152417.xml · nonDerivative · entry 1 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,549,982 F1 · kind: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on September 11, 2023, and contemplated quarterly sales of 25,000 shares with a limit price of $100.00 per share. The Rule 10b5-1 trading plan has reached the maximum number of shares to be sold under such plan and has terminated. F2 · price: The transaction was executed in multiple trades ranging from $170.75 to $171.74. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 11, 2024 Filed Mar 12, 2024 00:27 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 1,314 | $174.00 | $228,630.61 |
DisclosureSEC source: 0001298711-24-000009 · wk-form4_1710203207.xml · nonDerivative · entry 14 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 1,612,262 F9 · kind: These sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish S. Krishnan. The Rule 10b5-1 trading plan started on September 11, 2023, and will terminate on September 11, 2024, and contemplates sales of 25,000 shares per quarter with a limit price of $100.00 per share. F10 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish S. Krishnan. F18 · price: The transaction was executed in multiple trades ranging from $173.6800 to $174.5000. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F12 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| March 11, 2024 Filed Mar 12, 2024 00:27 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 3,359 | $173.09 | $581,402.26 |
DisclosureSEC source: 0001298711-24-000009 · wk-form4_1710203207.xml · nonDerivative · entry 13 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 1,613,576 F9 · kind: These sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish S. Krishnan. The Rule 10b5-1 trading plan started on September 11, 2023, and will terminate on September 11, 2024, and contemplates sales of 25,000 shares per quarter with a limit price of $100.00 per share. F10 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish S. Krishnan. F17 · price: The transaction was executed in multiple trades ranging from $172.5800 to $173.5500. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F12 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| March 11, 2024 Filed Mar 12, 2024 00:27 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 2,816 | $172.06 | $484,518.99 |
DisclosureSEC source: 0001298711-24-000009 · wk-form4_1710203207.xml · nonDerivative · entry 12 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 1,616,935 F9 · kind: These sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish S. Krishnan. The Rule 10b5-1 trading plan started on September 11, 2023, and will terminate on September 11, 2024, and contemplates sales of 25,000 shares per quarter with a limit price of $100.00 per share. F10 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish S. Krishnan. F16 · price: The transaction was executed in multiple trades ranging from $171.5700 to $172.5500. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F12 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| March 11, 2024 Filed Mar 12, 2024 00:27 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 8,002 | $170.93 | $1,367,769.86 |
DisclosureSEC source: 0001298711-24-000009 · wk-form4_1710203207.xml · nonDerivative · entry 11 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 1,619,751 F9 · kind: These sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish S. Krishnan. The Rule 10b5-1 trading plan started on September 11, 2023, and will terminate on September 11, 2024, and contemplates sales of 25,000 shares per quarter with a limit price of $100.00 per share. F10 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish S. Krishnan. F15 · price: The transaction was executed in multiple trades ranging from $170.5400 to $171.5100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F12 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| March 11, 2024 Filed Mar 12, 2024 00:27 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 5,109 | $170.32 | $870,185.83 |
DisclosureSEC source: 0001298711-24-000009 · wk-form4_1710203207.xml · nonDerivative · entry 10 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 1,627,753 F9 · kind: These sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish S. Krishnan. The Rule 10b5-1 trading plan started on September 11, 2023, and will terminate on September 11, 2024, and contemplates sales of 25,000 shares per quarter with a limit price of $100.00 per share. F10 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish S. Krishnan. F14 · price: The transaction was executed in multiple trades ranging from $169.5400 to $170.5300. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F12 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| March 11, 2024 Filed Mar 12, 2024 00:27 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 2,254 | $168.88 | $380,660.48 |
DisclosureSEC source: 0001298711-24-000009 · wk-form4_1710203207.xml · nonDerivative · entry 9 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 1,632,862 F9 · kind: These sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish S. Krishnan. The Rule 10b5-1 trading plan started on September 11, 2023, and will terminate on September 11, 2024, and contemplates sales of 25,000 shares per quarter with a limit price of $100.00 per share. F10 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish S. Krishnan. F13 · price: The transaction was executed in multiple trades ranging from $168.4900 to $169.3300. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F12 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| March 11, 2024 Filed Mar 12, 2024 00:27 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 2,146 | $167.99 | $360,511.26 |
DisclosureSEC source: 0001298711-24-000009 · wk-form4_1710203207.xml · nonDerivative · entry 8 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 1,635,116 F9 · kind: These sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish S. Krishnan. The Rule 10b5-1 trading plan started on September 11, 2023, and will terminate on September 11, 2024, and contemplates sales of 25,000 shares per quarter with a limit price of $100.00 per share. F10 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish S. Krishnan. F11 · price: The transaction was executed in multiple trades ranging from $167.4900 to $168.4800. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F12 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| March 11, 2024 Filed Mar 12, 2024 00:27 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 800 | $174.13 | $139,305.04 |
DisclosureSEC source: 0001298711-24-000009 · wk-form4_1710203207.xml · nonDerivative · entry 7 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,550,882 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on September 11, 2023, and will terminate on September 11, 2024, and contemplates sales of 25,000 shares per quarter with a limit price of $100.00 per share. F8 · price: The transaction was executed in multiple trades ranging from $173.9000 to $174.5000. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 11, 2024 Filed Mar 12, 2024 00:27 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 3,587 | $173.30 | $621,623.87 |
DisclosureSEC source: 0001298711-24-000009 · wk-form4_1710203207.xml · nonDerivative · entry 6 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,551,682 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on September 11, 2023, and will terminate on September 11, 2024, and contemplates sales of 25,000 shares per quarter with a limit price of $100.00 per share. F7 · price: The transaction was executed in multiple trades ranging from $172.9000 to $173.8800. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 11, 2024 Filed Mar 12, 2024 00:27 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 2,800 | $172.21 | $482,175.96 |
DisclosureSEC source: 0001298711-24-000009 · wk-form4_1710203207.xml · nonDerivative · entry 5 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,555,269 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on September 11, 2023, and will terminate on September 11, 2024, and contemplates sales of 25,000 shares per quarter with a limit price of $100.00 per share. F6 · price: The transaction was executed in multiple trades ranging from $171.8300 to $172.8000. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 11, 2024 Filed Mar 12, 2024 00:27 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 5,469 | $171.09 | $935,712.54 |
DisclosureSEC source: 0001298711-24-000009 · wk-form4_1710203207.xml · nonDerivative · entry 4 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,558,069 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on September 11, 2023, and will terminate on September 11, 2024, and contemplates sales of 25,000 shares per quarter with a limit price of $100.00 per share. F5 · price: The transaction was executed in multiple trades ranging from $170.7600 to $171.7500. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 11, 2024 Filed Mar 12, 2024 00:27 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 8,040 | $170.42 | $1,370,173.58 |
DisclosureSEC source: 0001298711-24-000009 · wk-form4_1710203207.xml · nonDerivative · entry 3 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,563,538 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on September 11, 2023, and will terminate on September 11, 2024, and contemplates sales of 25,000 shares per quarter with a limit price of $100.00 per share. F4 · price: The transaction was executed in multiple trades ranging from $169.7600 to $170.7500. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 11, 2024 Filed Mar 12, 2024 00:27 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 1,646 | $168.96 | $278,103.88 |
DisclosureSEC source: 0001298711-24-000009 · wk-form4_1710203207.xml · nonDerivative · entry 2 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,571,578 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on September 11, 2023, and will terminate on September 11, 2024, and contemplates sales of 25,000 shares per quarter with a limit price of $100.00 per share. F3 · price: The transaction was executed in multiple trades ranging from $168.5700 to $169.4900. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 11, 2024 Filed Mar 12, 2024 00:27 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 2,658 | $168.15 | $446,944.83 |
DisclosureSEC source: 0001298711-24-000009 · wk-form4_1710203207.xml · nonDerivative · entry 1 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,573,224 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on September 11, 2023, and will terminate on September 11, 2024, and contemplates sales of 25,000 shares per quarter with a limit price of $100.00 per share. F2 · price: The transaction was executed in multiple trades ranging from $167.5700 to $168.5600. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| February 29, 2024 Filed Mar 2, 2024 01:13 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantPerformance Stock Units · Derivative | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001298711-24-000006 · wk-form4_1709341989.xml · derivative · entry 8 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires not disclosed F11 · derivative.exercise_price: Each PSU represents a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31, 2024, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. F12 · shares: The number of PSUs in this column represents the number of shares of common stock the Reporting Person will receive assuming achievement of all of the performance criteria set by the Company's Compensation Committee for this PSU award and full vesting of this PSU award. F13 · derivative.exercise_date: If any applicable portion of the performance criteria have been achieved, the PSU award shall vest in two equal annual installments (February 28, 2025 and February 28, 2026). F14 · derivative.expiration_date: If some or all of the performance criteria are not achieved, the applicable portion of the PSU award will be forfeited. Read SEC document |
| February 28, 2024 Filed Mar 2, 2024 01:13 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Exercise / conversionPerformance Stock Units · Derivative | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001298711-24-000006 · wk-form4_1709341989.xml · derivative · entry 7 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31, 2023, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. All of the performance criteria were achieved and one-half of the PSUs granted, or 7,500 PSUs, vested on February 28, 2024. F10 · derivative.exercise_date: 15,000 PSUs were granted on February 28, 2023, that vest in two equal annual installments with the first installment vesting on February 28, 2024. F10 · derivative.expiration_date: 15,000 PSUs were granted on February 28, 2023, that vest in two equal annual installments with the first installment vesting on February 28, 2024. Read SEC document |
| February 28, 2024 Filed Mar 2, 2024 01:13 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Tax withholdingCommon Stock | 5,785 | $163.08 | $943,417.80 |
DisclosureSEC source: 0001298711-24-000006 · wk-form4_1709341989.xml · nonDerivative · entry 4 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 1,637,262 F5 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish S. Krishnan. F7 · shares: Represents number of shares of common stock surrendered by the Reporting Person's spouse, Krish M. Krishnan, to the Company for tax withholding upon the vesting of 12,500 PSUs on February 28, 2024. F3 · price: The closing price on February 28, 2024 of the Company's common stock on NASDAQ. F6 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| February 28, 2024 Filed Mar 2, 2024 01:13 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Exercise / conversionCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001298711-24-000006 · wk-form4_1709341989.xml · nonDerivative · entry 3 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 1,643,047 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: 25,000 PSUs were granted on February 28, 2023, to the Reporting Person's spouse, Krish S. Krishnan. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31, 2023, as approved by the Company's Compensation Committee, and the Reporting Person's spouse continued service to the Company on each applicable vesting date following such achievement. All of the performance criteria were achieved and one-half of the PSUs granted, or 12,500 PSUs, vested on February 28, 2024. F5 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish S. Krishnan. F6 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| February 28, 2024 Filed Mar 2, 2024 01:13 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Tax withholdingCommon Stock | 3,471 | $163.08 | $566,050.68 |
DisclosureSEC source: 0001298711-24-000006 · wk-form4_1709341989.xml · nonDerivative · entry 2 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,575,882 F2 · shares: Represents the number of shares of common stock surrendered to the Company for tax withholding upon the vesting of 7,500 PSUs on February 28, 2024. F3 · price: The closing price on February 28, 2024 of the Company's common stock on NASDAQ. Read SEC document |
| February 28, 2024 Filed Mar 2, 2024 01:13 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Exercise / conversionCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001298711-24-000006 · wk-form4_1709341989.xml · nonDerivative · entry 1 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,579,353 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: 15,000 performance stock units ("PSUs") were granted on February 28, 2023. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31, 2023, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. All of the performance criteria were achieved and one-half of the PSUs granted, or 7,500 PSUs, vested on February 28, 2024. Read SEC document |
| February 26, 2024 Filed Feb 29, 2024 02:39 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Tax withholdingCommon Stock | 2,353 | $157.00 | $369,421.00 |
DisclosureSEC source: 0001298711-24-000004 · wk-form4_1709174331.xml · nonDerivative · entry 1 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,571,853 F1 · shares: Represents number of shares of common stock surrendered to the Company for tax withholding upon the vesting of 7,100 shares of restricted stock on February 26, 2024. F2 · price: The closing price on February 26, 2024 of the Company's common stock on NASDAQ. Read SEC document |
| December 11, 2023 Filed Dec 12, 2023 22:23 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 100 | $107.66 | $10,766.00 |
DisclosureSEC source: 0001298711-23-000020 · wk-form4_1702419802.xml · nonDerivative · entry 8 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 1,634,338 F5 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish S. Krishnan. The Rule 10b5-1 trading plan started on September 11, 2023 and will terminate on September 11, 2024 and contemplates sales of 25,000 shares per quarter with a limit price of $100.00 per share. F6 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish S. Krishnan. F8 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| December 11, 2023 Filed Dec 12, 2023 22:23 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 14,237 | $106.11 | $1,510,666.71 |
DisclosureSEC source: 0001298711-23-000020 · wk-form4_1702419802.xml · nonDerivative · entry 7 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 1,634,438 F5 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish S. Krishnan. The Rule 10b5-1 trading plan started on September 11, 2023 and will terminate on September 11, 2024 and contemplates sales of 25,000 shares per quarter with a limit price of $100.00 per share. F6 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish S. Krishnan. F10 · price: The transaction was executed in multiple trades ranging from $105.9000 to $106.5500. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F8 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| December 11, 2023 Filed Dec 12, 2023 22:23 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 6,263 | $105.50 | $660,770.93 |
DisclosureSEC source: 0001298711-23-000020 · wk-form4_1702419802.xml · nonDerivative · entry 6 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 1,648,675 F5 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish S. Krishnan. The Rule 10b5-1 trading plan started on September 11, 2023 and will terminate on September 11, 2024 and contemplates sales of 25,000 shares per quarter with a limit price of $100.00 per share. F6 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish S. Krishnan. F9 · price: The transaction was executed in multiple trades ranging from $104.9000 to $105.8900. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F8 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| December 11, 2023 Filed Dec 12, 2023 22:23 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 4,400 | $104.41 | $459,424.24 |
DisclosureSEC source: 0001298711-23-000020 · wk-form4_1702419802.xml · nonDerivative · entry 5 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 1,654,938 F5 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish S. Krishnan. The Rule 10b5-1 trading plan started on September 11, 2023 and will terminate on September 11, 2024 and contemplates sales of 25,000 shares per quarter with a limit price of $100.00 per share. F6 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish S. Krishnan. F7 · price: The transaction was executed in multiple trades ranging from $103.9000 to $104.8800. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F8 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| December 11, 2023 Filed Dec 12, 2023 22:23 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 100 | $107.66 | $10,766.00 |
DisclosureSEC source: 0001298711-23-000020 · wk-form4_1702419802.xml · nonDerivative · entry 4 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,574,206 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on September 11, 2023 and will terminate on September 11, 2024 and contemplates sales of 25,000 shares per quarter with a limit price of $100.00 per share. Read SEC document |
| December 11, 2023 Filed Dec 12, 2023 22:23 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 17,505 | $106.04 | $1,856,240.70 |
DisclosureSEC source: 0001298711-23-000020 · wk-form4_1702419802.xml · nonDerivative · entry 3 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,574,306 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on September 11, 2023 and will terminate on September 11, 2024 and contemplates sales of 25,000 shares per quarter with a limit price of $100.00 per share. F4 · price: The transaction was executed in multiple trades ranging from $105.5600 to $106.5500. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| December 11, 2023 Filed Dec 12, 2023 22:23 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 4,541 | $105.06 | $477,087.00 |
DisclosureSEC source: 0001298711-23-000020 · wk-form4_1702419802.xml · nonDerivative · entry 2 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,591,811 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on September 11, 2023 and will terminate on September 11, 2024 and contemplates sales of 25,000 shares per quarter with a limit price of $100.00 per share. F3 · price: The transaction was executed in multiple trades ranging from $104.5600 to $105.5400. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| December 11, 2023 Filed Dec 12, 2023 22:23 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 2,854 | $104.26 | $297,569.17 |
DisclosureSEC source: 0001298711-23-000020 · wk-form4_1702419802.xml · nonDerivative · entry 1 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,596,352 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on September 11, 2023 and will terminate on September 11, 2024 and contemplates sales of 25,000 shares per quarter with a limit price of $100.00 per share. F2 · price: The transaction was executed in multiple trades ranging from $103.5600 to $104.5500. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| September 11, 2023 Filed Sep 12, 2023 22:01 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 2,110 | $129.10 | $272,403.74 |
DisclosureSEC source: 0001298711-23-000017 · wk-form4_1694556050.xml · nonDerivative · entry 10 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 1,659,338 F7 · kind: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish Krishnan. The Rule 10b5-1 trading plan adopted by the Reporting Person's spouse started on September 11, 2023, and will terminate on September 11, 2024, and contemplates sales of 25,000 shares per quarter with a limit price of $100.00 per share. F8 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish Krishnan. F6 · price: The transaction was executed in multiple trades ranging from $128.7400 to $129.4200. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F9 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| September 11, 2023 Filed Sep 12, 2023 22:01 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 10,557 | $128.37 | $1,355,215.81 |
DisclosureSEC source: 0001298711-23-000017 · wk-form4_1694556050.xml · nonDerivative · entry 9 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 1,661,448 F7 · kind: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish Krishnan. The Rule 10b5-1 trading plan adopted by the Reporting Person's spouse started on September 11, 2023, and will terminate on September 11, 2024, and contemplates sales of 25,000 shares per quarter with a limit price of $100.00 per share. F8 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish Krishnan. F5 · price: The transaction was executed in multiple trades ranging from $127.7350 to $128.7300. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F9 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| September 11, 2023 Filed Sep 12, 2023 22:01 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 1,873 | $127.18 | $238,214.13 |
DisclosureSEC source: 0001298711-23-000017 · wk-form4_1694556050.xml · nonDerivative · entry 8 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 1,672,005 F7 · kind: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish Krishnan. The Rule 10b5-1 trading plan adopted by the Reporting Person's spouse started on September 11, 2023, and will terminate on September 11, 2024, and contemplates sales of 25,000 shares per quarter with a limit price of $100.00 per share. F8 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish Krishnan. F4 · price: The transaction was executed in multiple trades ranging from $126.7200 to $127.7100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F9 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| September 11, 2023 Filed Sep 12, 2023 22:01 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 5,452 | $126.17 | $687,866.30 |
DisclosureSEC source: 0001298711-23-000017 · wk-form4_1694556050.xml · nonDerivative · entry 7 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 1,673,878 F7 · kind: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish Krishnan. The Rule 10b5-1 trading plan adopted by the Reporting Person's spouse started on September 11, 2023, and will terminate on September 11, 2024, and contemplates sales of 25,000 shares per quarter with a limit price of $100.00 per share. F8 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish Krishnan. F3 · price: The transaction was executed in multiple trades ranging from $125.7200 to $126.6800. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F9 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| September 11, 2023 Filed Sep 12, 2023 22:01 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 5,008 | $125.23 | $627,139.32 |
DisclosureSEC source: 0001298711-23-000017 · wk-form4_1694556050.xml · nonDerivative · entry 6 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 1,679,330 F7 · kind: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish Krishnan. The Rule 10b5-1 trading plan adopted by the Reporting Person's spouse started on September 11, 2023, and will terminate on September 11, 2024, and contemplates sales of 25,000 shares per quarter with a limit price of $100.00 per share. F8 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish Krishnan. F2 · price: The transaction was executed in multiple trades ranging from $124.7100 to $125.6950. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F9 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| September 11, 2023 Filed Sep 12, 2023 22:01 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 2,110 | $129.10 | $272,403.95 |
DisclosureSEC source: 0001298711-23-000017 · wk-form4_1694556050.xml · nonDerivative · entry 5 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,599,206 F1 · kind: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on September 11, 2023, and will terminate on September 11, 2024, and contemplates sales of 25,000 shares per quarter with a limit price of $100.00 per share. F6 · price: The transaction was executed in multiple trades ranging from $128.7400 to $129.4200. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| September 11, 2023 Filed Sep 12, 2023 22:01 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 10,557 | $128.37 | $1,355,215.81 |
DisclosureSEC source: 0001298711-23-000017 · wk-form4_1694556050.xml · nonDerivative · entry 4 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,601,316 F1 · kind: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on September 11, 2023, and will terminate on September 11, 2024, and contemplates sales of 25,000 shares per quarter with a limit price of $100.00 per share. F5 · price: The transaction was executed in multiple trades ranging from $127.7350 to $128.7300. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| September 11, 2023 Filed Sep 12, 2023 22:01 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 1,874 | $127.18 | $238,341.50 |
DisclosureSEC source: 0001298711-23-000017 · wk-form4_1694556050.xml · nonDerivative · entry 3 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,611,873 F1 · kind: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on September 11, 2023, and will terminate on September 11, 2024, and contemplates sales of 25,000 shares per quarter with a limit price of $100.00 per share. F4 · price: The transaction was executed in multiple trades ranging from $126.7200 to $127.7100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| September 11, 2023 Filed Sep 12, 2023 22:01 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 5,452 | $126.17 | $687,865.76 |
DisclosureSEC source: 0001298711-23-000017 · wk-form4_1694556050.xml · nonDerivative · entry 2 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,613,747 F1 · kind: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on September 11, 2023, and will terminate on September 11, 2024, and contemplates sales of 25,000 shares per quarter with a limit price of $100.00 per share. F3 · price: The transaction was executed in multiple trades ranging from $125.7200 to $126.6800. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| September 11, 2023 Filed Sep 12, 2023 22:01 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 5,007 | $125.23 | $627,014.09 |
DisclosureSEC source: 0001298711-23-000017 · wk-form4_1694556050.xml · nonDerivative · entry 1 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,619,199 F1 · kind: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on September 11, 2023, and will terminate on September 11, 2024, and contemplates sales of 25,000 shares per quarter with a limit price of $100.00 per share. F2 · price: The transaction was executed in multiple trades ranging from $124.7100 to $125.6950. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 22:23 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 400 | $117.61 | $47,042.00 |
DisclosureSEC source: 0001298711-23-000015 · wk-form4_1685744623.xml · nonDerivative · entry 6 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 1,684,338 F4 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish Krishnan. F7 · price: The transaction was executed in multiple trades ranging from $117.5500 to $117.7200. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F5 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 22:23 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 5,716 | $116.95 | $668,485.06 |
DisclosureSEC source: 0001298711-23-000015 · wk-form4_1685744623.xml · nonDerivative · entry 5 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 1,684,738 F4 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish Krishnan. F6 · price: The transaction was executed in multiple trades ranging from $116.5200 to $117.5000. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F5 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 22:23 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 18,884 | $116.00 | $2,190,449.58 |
DisclosureSEC source: 0001298711-23-000015 · wk-form4_1685744623.xml · nonDerivative · entry 4 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 1,690,454 F4 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish Krishnan. F1 · price: The transaction was executed in multiple trades ranging from $115.5200 to $116.5100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F5 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 22:23 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 300 | $117.57 | $35,271.99 |
DisclosureSEC source: 0001298711-23-000015 · wk-form4_1685744623.xml · nonDerivative · entry 3 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,624,206 F3 · price: The transaction was executed in multiple trades ranging from $117.5500 to $117.6000. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 22:23 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 4,557 | $116.86 | $532,541.96 |
DisclosureSEC source: 0001298711-23-000015 · wk-form4_1685744623.xml · nonDerivative · entry 2 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,624,506 F2 · price: The transaction was executed in multiple trades ranging from $116.5200 to $117.5100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 22:23 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 20,143 | $115.98 | $2,336,098.53 |
DisclosureSEC source: 0001298711-23-000015 · wk-form4_1685744623.xml · nonDerivative · entry 1 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,629,063 F1 · price: The transaction was executed in multiple trades ranging from $115.5200 to $116.5100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.